HRP20220060T1 - Predlijekovi supstituiranih derivata triazola i njihova upotreba - Google Patents
Predlijekovi supstituiranih derivata triazola i njihova upotreba Download PDFInfo
- Publication number
- HRP20220060T1 HRP20220060T1 HRP20220060TT HRP20220060T HRP20220060T1 HR P20220060 T1 HRP20220060 T1 HR P20220060T1 HR P20220060T T HRP20220060T T HR P20220060TT HR P20220060 T HRP20220060 T HR P20220060T HR P20220060 T1 HRP20220060 T1 HR P20220060T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- general formula
- syndrome
- solvates
- formula
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 6
- 201000008284 inappropriate ADH syndrome Diseases 0.000 claims 6
- 208000030613 peripheral artery disease Diseases 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000030090 Acute Disease Diseases 0.000 claims 3
- 206010003445 Ascites Diseases 0.000 claims 3
- 206010007556 Cardiac failure acute Diseases 0.000 claims 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 3
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
- 208000005171 Dysmenorrhea Diseases 0.000 claims 3
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 3
- 206010021036 Hyponatraemia Diseases 0.000 claims 3
- 206010030113 Oedema Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 230000010060 microvascular dysfunction Effects 0.000 claims 3
- 201000011461 pre-eclampsia Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- YVYCJMVBBCGZIS-ZDUSSCGKSA-N [(2S)-3-[1-[[5-carbamoyl-1-[3-(trifluoromethyl)pyridin-2-yl]-1,2,4-triazol-3-yl]methyl]-3-(4-chlorophenyl)-5-oxo-1,2,4-triazol-4-yl]-1,1,1-trifluoropropan-2-yl] dihydrogen phosphate Chemical compound NC(=O)C1=NC(CN2N=C(N(C[C@H](OP(O)(O)=O)C(F)(F)F)C2=O)C2=CC=C(Cl)C=C2)=NN1C1=NC=CC=C1C(F)(F)F YVYCJMVBBCGZIS-ZDUSSCGKSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003119 guanylate cyclase activator Substances 0.000 claims 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940123073 Angiotensin antagonist Drugs 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 239000002369 angiotensin antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- NSBNXCZCLRBQTA-UHFFFAOYSA-N dibenzyl bis(phenylmethoxy)phosphoryl phosphate Chemical compound C=1C=CC=CC=1COP(OP(=O)(OCC=1C=CC=CC=1)OCC=1C=CC=CC=1)(=O)OCC1=CC=CC=C1 NSBNXCZCLRBQTA-UHFFFAOYSA-N 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000004041 inotropic agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 claims 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Spoj opće formule (I)
[image]
u kojoj
R1 predstavlja skupinu s formulom
[image]
u kojoj
# predstavlja točku vezivanja za prsten 1,2,4-triazolil,
ili jedna od njegovih farmaceutski prihvatljivih soli, njegovih solvata ili solvata njegovih soli.
2. Spoj opće formule (I) prema patentnom zahtjevu 1, naznačen time što
R1 predstavlja skupinu s formulom
[image]
u kojoj
# predstavlja točku vezivanja za prsten 1,2,4-triazolil.
3. (2S)-3-[1-({5-Karbamoil-1-[3-(trifluorometil)piridin-2-il]-1H-1,2,4-triazol-3-il}metil)-3-(4-klorofenil)-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-1,1,1-trifluoropropan-2-il dihidrogenfosfat prema patentnom zahtjevu 1 s formulom u nastavku
[image]
ili jedna od njegovih farmaceutski prihvatljivih soli, njegovih solvata ili solvata njegovih soli.
4. (2S)-3-[1-({5-Karbamoil-1-[3-(trifluorometil)piridin-2-il]-1H-1,2,4-triazol-3-il}metil)-3-(4-klorofenil)-5-okso-1,5-dihidro-4H-1,2,4-triazol-4-il]-1,1,1-trifluoropropan-2-il dihidrogenfosfat prema patentnom zahtjevu 1 s formulom u nastavku
[image]
5. Postupak za pripravu spoja opće formule (I) ili jedne od njegovih farmaceutski prihvatljivih soli, njegovih solvata ili solvata njegovih soli prema patentnom zahtjevu 1, naznačen time što
[A] spoj s formulom
[image]
u kojoj
R1 ima značenje kako je definirano za spojeve opće formule (I) navedeno u zahtjevu 1, reagira u prvom koraku s fosfornim oksikloridom i u drugom koraku se hidrolizira da se dobije spoj opće formule (I),
ili
[B] spoj s formulom
[image]
u kojoj
R1 ima značenje kako je definirano za spojeve opće formule (I) navedeno u zahtjevu 1, reagira u prvom koraku s tetrabenzil difosfatom i u drugom koraku benzilne skupine su uklonjene pod redukcijskim uvjetima kako bi se dobio spoj opće formule (I),
po izboru slijedi, gdje je prikladno, prevođenje spoja opće formule (I) u njegove odgovarajuće farmaceutski prihvatljive soli, njegove solvate ili solvate njegovih soli obradom s odgovarajućim otapalima i/ili bazama.
6. Spoj kako je definiran u bilo kojem od patentnih zahtjeva 1 do 4 naznačen time što je za upotrebu u liječenju i/ili prevenciji bolesti.
7. Spoj kako je definiran u bilo kojem od patentnih zahtjeva 1 do 4 naznačen time što je za upotrebu u liječenju i/ili prevenciji akutnih i kroničnih bubrežnih bolesti uključujući dijabetičku nefropatiju, akutno i kronično zatajenje srca, preeklampsiju, bolest perifernih arterija (PAD), koronarnu mikrovaskularnu disfunkciju (CMD), Rainaudov sindrom, dismenoreju, kardiorenalni sindrom, hipervolemijsku i euvolemijsku hiponatremiju, cirozu jetre, ascites, edem i sindrom neprimjerenog lučenja ADH (SIADH).
8. Upotreba spoja kako je definiran u bilo kojem od patentnih zahtjeva 1 do 4 naznačena time što je za proizvodnju farmaceutskog pripravka za liječenje i/ili prevenciju akutnih i kroničnih bubrežnih bolesti uključujući dijabetičku nefropatiju, akutno i kronično zatajenje srca, preeklampsiju, bolest perifernih arterija (PAD), koronarnu mikrovaskularnu disfunkciju (CMD), Rainaudov sindrom, dismenoreju, kardiorenalni sindrom, hipervolemijsku i euvolemijsku hiponatremiju, cirozu jetre, ascites, edem i sindrom neprimjerenog lučenja ADH (SIADH).
9. Farmaceutski pripravak naznačen time što sadrži spoj kako je definiran u bilo kojem od patentnih zahtjeva 1 do 4 i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
10. Farmaceutski pripravak prema patentnom zahtjevu 9 naznačen time što sadrži jedan ili više prvih aktivnih sastojaka, naročito spojeve opće formule (I) prema bilo kojem od zahtjeva 1 do 4, i jedan ili više daljnjih aktivnih sastojaka, naročito jedno ili više dodatnih terapijskih sredstava odabranih iz skupine koju čine diuretici, antagonisti All angiotenzina, inhibitori ACE, blokatori beta-receptora, antagonisti mineralokortikoidnih receptora, organski nitrati, donori NO, aktivatori i stimulatori topive gvanilat ciklaze, i pozitivno-inotropna sredstva, protuupalna sredstva, imunosupresivna sredstva, veziva fosfata i/ili spojevi koji moduliraju metabolizam vitamina D.
11. Farmaceutski pripravak kako je definiran u patentnom zahtjevu 9 ili 10 naznačen time što je za upotrebu u liječenju i/ili prevenciji akutnih i kroničnih bubrežnih bolesti uključujući dijabetičku nefropatiju, akutnog i kroničnog zatajenja srca, preeklampsije, bolesti perifernih arterija (PAD), koronarne mikrovaskularne disfunkcije (CMD), Rainaudovog sindroma, dismenoreje, kardiorenalnog sindroma, hipervolemijske i euvolemijske hiponatremije, ciroze jetre, ascites, edema i sindrom neprimjerenog lučenja ADH (SIADH).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17197935 | 2017-10-24 | ||
| PCT/EP2018/078364 WO2019081292A1 (en) | 2017-10-24 | 2018-10-17 | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
| EP18785394.0A EP3700913B1 (en) | 2017-10-24 | 2018-10-17 | Prodrugs of substituted triazole derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220060T1 true HRP20220060T1 (hr) | 2022-04-15 |
Family
ID=60162099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220060TT HRP20220060T1 (hr) | 2017-10-24 | 2018-10-17 | Predlijekovi supstituiranih derivata triazola i njihova upotreba |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US11298367B2 (hr) |
| EP (1) | EP3700913B1 (hr) |
| JP (1) | JP2021500365A (hr) |
| KR (1) | KR20200069361A (hr) |
| CN (1) | CN111225921A (hr) |
| AR (1) | AR113791A1 (hr) |
| AU (1) | AU2018356352A1 (hr) |
| BR (1) | BR112020007983A2 (hr) |
| CA (1) | CA3079767A1 (hr) |
| CL (1) | CL2020001076A1 (hr) |
| CO (1) | CO2020004945A2 (hr) |
| CR (1) | CR20200176A (hr) |
| CU (1) | CU24604B1 (hr) |
| CY (1) | CY1124938T1 (hr) |
| DK (1) | DK3700913T3 (hr) |
| DO (1) | DOP2020000076A (hr) |
| EA (1) | EA202091025A1 (hr) |
| EC (1) | ECSP20023056A (hr) |
| ES (1) | ES2906305T3 (hr) |
| HR (1) | HRP20220060T1 (hr) |
| HU (1) | HUE057278T2 (hr) |
| IL (1) | IL273949A (hr) |
| JO (1) | JOP20200099A1 (hr) |
| LT (1) | LT3700913T (hr) |
| MA (1) | MA50438B1 (hr) |
| MX (1) | MX2020004191A (hr) |
| NI (1) | NI202000030A (hr) |
| PE (1) | PE20210394A1 (hr) |
| PH (1) | PH12020550473A1 (hr) |
| PL (1) | PL3700913T3 (hr) |
| PT (1) | PT3700913T (hr) |
| RS (1) | RS62984B1 (hr) |
| SG (1) | SG11202003049WA (hr) |
| SI (1) | SI3700913T1 (hr) |
| TW (1) | TW201932117A (hr) |
| UA (1) | UA126456C2 (hr) |
| UY (1) | UY37948A (hr) |
| WO (1) | WO2019081292A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021259852A1 (en) | 2020-06-25 | 2021-12-30 | Bayer Aktiengesellschaft | Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives |
| WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| EA010132B1 (ru) | 2003-12-22 | 2008-06-30 | Пфайзер Инк. | Производные триазола в качестве антагонистов вазопрессина |
| MXPA06012510A (es) | 2004-04-28 | 2006-12-15 | Pfizer | Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via. |
| MX2010004673A (es) * | 2007-11-06 | 2010-05-27 | Astrazeneca Ab | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos. |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| AR076542A1 (es) * | 2009-05-22 | 2011-06-22 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida |
| RS56312B1 (sr) | 2010-02-27 | 2017-12-29 | Bayer Ip Gmbh | Ariltriazoloni spojeni sa bis-arilom i njihova upotreba |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| PE20130779A1 (es) | 2010-07-09 | 2013-06-21 | Bayer Ip Gmbh | Pirimidinas y triazinas condensadas y su uso |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| WO2012112363A1 (en) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| EA030055B1 (ru) * | 2013-10-16 | 2018-06-29 | Байер Кропсайенс Акциенгезелльшафт | Комбинации активных соединений, содержащие (тио)карбоксамидное производное и фунгицидное соединение |
| CA2966256A1 (en) | 2014-11-03 | 2016-05-12 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
| UY36571A (es) * | 2015-03-05 | 2016-09-30 | Bayer Cropscience Ag | Combinaciones de compuestos activos |
| WO2017191105A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
| JP6911052B2 (ja) | 2016-05-03 | 2021-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | オキソアルキル置換フェニルトリアゾール誘導体およびその使用 |
| US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| WO2017191114A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
| US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
| UY37221A (es) | 2016-05-03 | 2017-11-30 | Bayer Pharma AG | Derivados de feniltriazol sustituidos con amida y usos de estos |
| US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
-
2018
- 2018-10-17 KR KR1020207014412A patent/KR20200069361A/ko not_active Application Discontinuation
- 2018-10-17 AU AU2018356352A patent/AU2018356352A1/en not_active Abandoned
- 2018-10-17 MX MX2020004191A patent/MX2020004191A/es unknown
- 2018-10-17 PE PE2020000813A patent/PE20210394A1/es unknown
- 2018-10-17 JO JOP/2020/0099A patent/JOP20200099A1/ar unknown
- 2018-10-17 BR BR112020007983-9A patent/BR112020007983A2/pt not_active Application Discontinuation
- 2018-10-17 HU HUE18785394A patent/HUE057278T2/hu unknown
- 2018-10-17 MA MA50438A patent/MA50438B1/fr unknown
- 2018-10-17 EP EP18785394.0A patent/EP3700913B1/en active Active
- 2018-10-17 CU CU2020000040A patent/CU24604B1/es unknown
- 2018-10-17 DK DK18785394.0T patent/DK3700913T3/da active
- 2018-10-17 PT PT187853940T patent/PT3700913T/pt unknown
- 2018-10-17 EA EA202091025A patent/EA202091025A1/ru unknown
- 2018-10-17 JP JP2020522855A patent/JP2021500365A/ja active Pending
- 2018-10-17 ES ES18785394T patent/ES2906305T3/es active Active
- 2018-10-17 CR CR20200176A patent/CR20200176A/es unknown
- 2018-10-17 CA CA3079767A patent/CA3079767A1/en not_active Abandoned
- 2018-10-17 CN CN201880068846.5A patent/CN111225921A/zh active Pending
- 2018-10-17 HR HRP20220060TT patent/HRP20220060T1/hr unknown
- 2018-10-17 LT LTEPPCT/EP2018/078364T patent/LT3700913T/lt unknown
- 2018-10-17 SG SG11202003049WA patent/SG11202003049WA/en unknown
- 2018-10-17 UA UAA202003139A patent/UA126456C2/uk unknown
- 2018-10-17 WO PCT/EP2018/078364 patent/WO2019081292A1/en active Application Filing
- 2018-10-17 RS RS20220036A patent/RS62984B1/sr unknown
- 2018-10-17 US US16/758,742 patent/US11298367B2/en active Active
- 2018-10-17 PL PL18785394T patent/PL3700913T3/pl unknown
- 2018-10-17 SI SI201830540T patent/SI3700913T1/sl unknown
- 2018-10-22 TW TW107137148A patent/TW201932117A/zh unknown
- 2018-10-24 AR ARP180103099A patent/AR113791A1/es unknown
- 2018-10-24 UY UY0001037948A patent/UY37948A/es not_active Application Discontinuation
-
2020
- 2020-04-13 IL IL273949A patent/IL273949A/en unknown
- 2020-04-21 EC ECSENADI202023056A patent/ECSP20023056A/es unknown
- 2020-04-22 CO CONC2020/0004945A patent/CO2020004945A2/es unknown
- 2020-04-22 CL CL2020001076A patent/CL2020001076A1/es unknown
- 2020-04-22 PH PH12020550473A patent/PH12020550473A1/en unknown
- 2020-04-23 NI NI202000030A patent/NI202000030A/es unknown
- 2020-05-06 DO DO2020000076A patent/DOP2020000076A/es unknown
-
2022
- 2022-02-01 CY CY20221100084T patent/CY1124938T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210648T1 (hr) | Amid-supstituirani derivati piridiniltriazola i njihova uporaba | |
| JP2019514945A5 (hr) | ||
| Paulis et al. | Key advances in antihypertensive treatment | |
| KR100712226B1 (ko) | 1,2-어닐링된 퀴놀린 유도체 | |
| HRP20220060T1 (hr) | Predlijekovi supstituiranih derivata triazola i njihova upotreba | |
| EP1919473B1 (fr) | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique | |
| JP3212036B2 (ja) | 置換アゾール、その製造方法およびその含有組成物 | |
| MX2022002952A (es) | Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo. | |
| Unger | Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? | |
| WO2013101281A1 (en) | Methods and compositions for treating parkinson's disease | |
| IL262708A (en) | Pretty metamorphous compounds of pyrazole for the treatment of diseases | |
| EP2005962B1 (en) | Therapeutic agent for inflammatory bowel disease | |
| CZ2004356A3 (cs) | Farmaceutická kompozice pro léčení nebo prevenci rakovin a použití účinných látek | |
| JP6778680B2 (ja) | 錠剤 | |
| WO1993013077A1 (en) | Angiotensin ii receptor antagonists | |
| US20140004203A1 (en) | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea | |
| DE4036645A1 (de) | Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung | |
| CN102485724A (zh) | 取代噻唑基吡唑并吡啶类化合物及其医药用途 | |
| CN100457103C (zh) | 非洛地平双层渗透泵控释药物组合物 | |
| CN104257622B (zh) | 一种帕利哌酮控释片及其制备方法 | |
| JP2009519998A (ja) | アミノアルコール誘導体の過活動膀胱の治療の為の使用 | |
| FI3661503T3 (fi) | PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ | |
| CA2318778A1 (en) | Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist | |
| JP2020529999A5 (hr) | ||
| Grange et al. | Selenofonsartan analogues: novel selenium-containing antihypertensive compounds |